|Year : 2016 | Volume
| Issue : 4 | Page : 339-341
Radiation therapy for a rare association of maxillary neoplasm in xeroderma pigmentosum: Is it really contraindicated?
Saurabh Samdariya1, Sumer Chand Jain2, Abhishek Onkar3, Chendil Viswanthan4
1 Department of Radiation Oncology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
2 Department of Dermatology, Government Bangur Hospital, Pali, Rajasthan, India
3 Department of Ophthalmology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
4 Department of Radiation Oncology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India
|Date of Web Publication||12-Jul-2016|
Department of Radiation Oncology, All India Institute of Medical Sciences, Room No 311, Resident Hostel, AIIMS Residential Complex, Basni Phase II, Jodhpur, Rajasthan
Source of Support: None, Conflict of Interest: None
Dermatologic malignancies are common in xeroderma pigmentosum (XP) patients; they can develop maxillary sinus cancers on rare occasions. Despite their extreme sensitivity to ultraviolet light, the patients of XP can be treated with standard doses of ionizing radiation for the treatment of cancers. The examples of use of radiotherapy as a treatment modality for maxillary neoplasms in patients of XP are rare. This report highlights a rare association of maxillary carcinoma in a patient of XP who received the tumoricidal doses of therapeutic X-rays with acceptable toxicities.
Keywords: Ionizing radiation, maxillary sinus carcinoma, toxicities, xeroderma pigmentosum
|How to cite this article:|
Samdariya S, Jain SC, Onkar A, Viswanthan C. Radiation therapy for a rare association of maxillary neoplasm in xeroderma pigmentosum: Is it really contraindicated?. Clin Cancer Investig J 2016;5:339-41
|How to cite this URL:|
Samdariya S, Jain SC, Onkar A, Viswanthan C. Radiation therapy for a rare association of maxillary neoplasm in xeroderma pigmentosum: Is it really contraindicated?. Clin Cancer Investig J [serial online] 2016 [cited 2020 Nov 26];5:339-41. Available from: https://www.ccij-online.org/text.asp?2016/5/4/339/186110
| Introduction|| |
Xeroderma pigmentosum (XP) is a hereditary autosomal recessive disorder characterized by mucocutaneous and ocular hypersensitivity to ultraviolet (UV) radiation with irreversible DNA damage and subsequent malignancies. The basic defect in XP is in nucleotide excision repair (NER), leading to deficient repair of DNA damaged by UV radiation. There are eight complementation groups identified from XPA to XPG and a variant form XP-V. These patients frequently develop a variety of skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. This case report illustrates the rare occurrence of maxillary carcinoma in a young patient of XP. It also highlights the fact that even though the patients of XP are sensitive to the ionizing effects of UV rays, use of therapeutic X-rays in the form of external beam radiotherapy (EBRT) can be a viable option in treating locally advanced maxillary cancers.
| Case Report|| |
A 26-year-old male, farmer by occupation and resident of Mysore district, Karnataka, India, was referred to the Department of Radiation Oncology, Victoria Hospital, Bengaluru, Karnataka, India. He had chief complaints of right-sided headache, swelling on the right side of the face, constant watering, and diminished vision of right eye since 3 months. Patient had been operated for recurrent skin malignancies of right nasal ala in past. He underwent wide local excision for basal cell carcinoma 4 years back and wide local excision with nasolabial flap reconstruction for dermatofibrosarcoma 1 year later.
On physical examination, there was diffuse freckling with multiple hyper- and hypo-pigmented macules on the face, neck, and extremities along with proptosis and exposure keratitis of the right eye. There was a diffuse, nontender, soft swelling over right maxillary sinus region. Anterior rhinoscopy showed a mass obstructing the right nasal cavity. A contrast-enhanced computed tomography scan showed moderately-enhancing mass lesion measuring approximately 5 cm × 4.5 cm × 3 cm in right maxillary sinus extending into nasal cavity, right ethmoid air cells, infratemporal fossa, pterygoid plates, right orbit, middle cranial fossa (medial to temporal lobe) [Figure 1]. There were no significantly enlarged lymph nodes on examination and imaging. Fine needle aspiration cytology from maxillary sinus mass revealed squamous cell carcinoma of right maxillary sinus. Hence, a final diagnosis of squamous cell carcinoma of right maxillary sinus cT4bN0M0 UICC Stage IVB was made.
|Figure 1: Axial computed tomography image showing enhancing mass lesion in right maxillary sinus extending into infratemporal fossa, pterygoid plates, right orbit|
Click here to view
The patient was planned for concomitant chemo-irradiation. He was counseled regarding the possible radiation-induced skin and mucosal reactions during the course of radiotherapy. After taking his informed written consent, he was treated by concomitant chemo-irradiation with 5 cycles of weekly cisplatin (40 mg/sqm) and radical EBRT using telecobalt gamma rays to a total dose of 66 Gy in 33 fractions using ipsilateral wedge pair and isocentric method for 6 weeks. He tolerated the treatment well with Radiation Therapy Oncology Group Grade II skin and Grade III mucosal toxicities and is being followed up. At 3 years of follow–up, he is disease free.
| Discussion|| |
XP is a rare autosomal recessive disorder of DNA repair, with a prevalence of 1 in a million. It was first described by Hebra and Kaposi in 1874. It is characterized by multiple pigmented lesions, marked photosensitivity, and xerosis. The underlying cause of XP is defective DNA NER mechanism. Affected patients are at 1000 times higher risk to develop a variety of skin cancers such as basal cell carcinoma, squamous cell carcinoma, and malignant melanoma, but association of maxillary carcinoma is very rare.
Sinonasal malignancies are rare entities with an incidence of approximately 1 in 500,000–1 in 1,000,000 people. Maxillary neoplasms are the most common among this category of tumors. They are more commonly seen in males of middle age group. Surgical resection with negative microscopic margins is the preferred treatment option. Early infrastructure lesions may be excised and cured by surgery alone, but for most other cases, irradiation is given postoperatively even if margins are negative. Extension of cancer to the base of the skull, nasopharynx, or sphenoid sinus contraindicates surgical excision. As in our patient, the tumor had spread to temporal lobe of brain, henceforth treated with concurrent chemoradiation.
The basic principles of management of carcinoma maxilla in XP patients remain unchanged. Literature review showed that patients of XP show difference in sensitivity to ionizing radiation.,, Some patients develop severe radiation-induced reactions during radiotherapy and some tolerate complete tumoricidal doses well with minimal reactions. Despite their extreme sensitivity to UV light, the patients of XP can be treated with standard doses of ionizing radiation for the treatment of cancers. The reports of use of radiotherapy as a treatment modality for maxillary neoplasms in patients of XP are rare. Our patient tolerated the treatment well with acceptable skin and mucosal toxicities.
| Conclusion|| |
XP patients are predisposed to develop skin malignancies, but rarely, squamous cell carcinoma of maxillary sinus may develop in these patients affecting the overall prognosis and quality of life. Management of these patients by concurrent chemo-irradiation is a good option in these types of cases. In contrast to exaggerated sensitivity to UV radiation, XP patients may tolerate therapeutic doses of ionizing radiation. Radiation therapy is an effective therapeutic modality for the treatment of maxillary neoplasm with XP. In view of short survival period of these patients, long-term clinical outcome and late effects of radiation therapy remain to be elucidated. While planning treatment by ionizing radiation, detailed counseling is needed regarding the precautions and intensive treatment of possible severe acute radiation reactions during the course of treatment in these patients.
The authors would like to thank the patient, his relatives, and every hospital staffs.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sahai P, Singh K, Sharma S, Kashyap S, Mohanti BK. Basal cell carcinoma in a child with xeroderma pigmentosum: Clinical response with electron beam radiation therapy. Indian J Dermatol Venereol Leprol 2013;79:533-5.
Webb S. Xeroderma pigmentosum. BMJ 2008;336:444-6.
Baisakh MR, Khalkho J, Khan MA. Multiple squamous cell carcinoma of face in a child with xeroderma pigmentosa: A case report. Australas J Cancer 2009;8:133-5.
Halpern J, Hopping B, Brostoff JM. Photosensitivity, corneal scarring and developmental delay: Xeroderma Pigmentosum in a tropical country. Cases J 2008;1:254.
Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH. Cockayne syndrome and xeroderma pigmentosum: DNA repair disorders with overlaps and paradoxes. Neurology 2000;55:1442-9.
Mendenhall WM, Werning JW, Pfister DG. Treatment of head and neck cancer. In: Devita VT, Hellman TS, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 9th
ed. Philadelphia: Lippincott William and Wilkins; 2011. p. 770-1.
Rogers PB, Plowman PN, Harris SJ, Arlett CF. Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol 2000;57:143-54.
DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012;132 (3 Pt 2):785-96.
DiGiovanna JJ, Patronas N, Katz D, Abangan D, Kraemer KH. Xeroderma pigmentosum: Spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. J Cutan Med Surg 1998;2:153-8.